D. Boral Capital Reiterates “Buy” Rating for Invivyd (NASDAQ:IVVD)

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating reaffirmed by stock analysts at D. Boral Capital in a research note issued on Monday,Benzinga reports. They presently have a $9.00 price objective on the stock. D. Boral Capital’s price objective points to a potential upside of 408.47% from the stock’s previous close.

IVVD has been the topic of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Invivyd in a report on Tuesday, February 4th. Morgan Stanley decreased their target price on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research report on Wednesday, November 20th. Finally, EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Invivyd presently has an average rating of “Buy” and an average target price of $7.89.

Invivyd Trading Up 46.3 %

NASDAQ IVVD opened at $1.77 on Monday. The stock has a market capitalization of $211.73 million, a price-to-earnings ratio of -0.90 and a beta of 0.61. The business’s 50 day moving average is $0.79 and its two-hundred day moving average is $0.86. Invivyd has a 12-month low of $0.35 and a 12-month high of $4.74.

Insider Buying and Selling

In other news, Director Terrance Mcguire sold 160,400 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $0.59, for a total value of $94,636.00. Following the completion of the transaction, the director now owns 4,202,679 shares in the company, valued at $2,479,580.61. This trade represents a 3.68 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders sold 816,466 shares of company stock valued at $423,214. 17.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Invivyd

Several institutional investors and hedge funds have recently made changes to their positions in the business. Two Sigma Investments LP increased its holdings in Invivyd by 125.3% during the 4th quarter. Two Sigma Investments LP now owns 367,100 shares of the company’s stock valued at $163,000 after acquiring an additional 204,188 shares in the last quarter. Two Sigma Advisers LP grew its position in shares of Invivyd by 1,276.5% in the fourth quarter. Two Sigma Advisers LP now owns 304,200 shares of the company’s stock valued at $135,000 after purchasing an additional 282,100 shares during the last quarter. Mithril II GP LP acquired a new stake in shares of Invivyd in the fourth quarter valued at approximately $4,981,000. Deutsche Bank AG increased its stake in shares of Invivyd by 35.2% during the 4th quarter. Deutsche Bank AG now owns 874,406 shares of the company’s stock worth $385,000 after purchasing an additional 227,463 shares in the last quarter. Finally, Jane Street Group LLC raised its position in shares of Invivyd by 290.5% during the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock worth $52,000 after purchasing an additional 87,358 shares during the last quarter. 70.36% of the stock is currently owned by hedge funds and other institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.